Allison Bratzel
Stock Analyst at Piper Sandler
(4.40)
# 269
Out of 4,842 analysts
38
Total ratings
55.17%
Success rate
22.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TYRA Tyra Biosciences | Assumes: Overweight | $33 | $8.94 | +269.13% | 1 | May 21, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $140 → $115 | $34.35 | +234.79% | 1 | Mar 17, 2025 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $4 → $6 | $2.88 | +108.33% | 1 | Mar 14, 2025 | |
| INZY Inozyme Pharma | Maintains: Overweight | $30 → $23 | $3.96 | +481.54% | 1 | Mar 11, 2025 | |
| ENGN enGene Holdings | Initiates: Overweight | $26 | $3.98 | +553.27% | 1 | Feb 18, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $620 → $725 | $576.24 | +25.82% | 13 | Jan 7, 2025 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $12 → $22 | $14.95 | +47.16% | 2 | Nov 14, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $15 → $23 | $19.19 | +19.85% | 2 | Nov 14, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $65 → $62 | $32.43 | +91.18% | 1 | Nov 14, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $28 → $42 | $28.86 | +45.53% | 3 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $10.62 | +107.16% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $2.63 | +52.09% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $3.26 | +513.50% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $2.04 | +880.39% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $44 | $8.43 | +421.95% | 1 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 | $64.93 | +54.01% | 2 | Feb 8, 2023 |
Tyra Biosciences
May 21, 2025
Assumes: Overweight
Price Target: $33
Current: $8.94
Upside: +269.13%
Ultragenyx Pharmaceutical
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $34.35
Upside: +234.79%
Akebia Therapeutics
Mar 14, 2025
Maintains: Overweight
Price Target: $4 → $6
Current: $2.88
Upside: +108.33%
Inozyme Pharma
Mar 11, 2025
Maintains: Overweight
Price Target: $30 → $23
Current: $3.96
Upside: +481.54%
enGene Holdings
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $3.98
Upside: +553.27%
argenx SE
Jan 7, 2025
Maintains: Overweight
Price Target: $620 → $725
Current: $576.24
Upside: +25.82%
Travere Therapeutics
Nov 14, 2024
Maintains: Neutral
Price Target: $12 → $22
Current: $14.95
Upside: +47.16%
Rigel Pharmaceuticals
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $19.19
Upside: +19.85%
Ionis Pharmaceuticals
Nov 14, 2024
Maintains: Overweight
Price Target: $65 → $62
Current: $32.43
Upside: +91.18%
Scholar Rock Holding
Oct 15, 2024
Maintains: Overweight
Price Target: $28 → $42
Current: $28.86
Upside: +45.53%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $10.62
Upside: +107.16%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $2.63
Upside: +52.09%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $3.26
Upside: +513.50%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $2.04
Upside: +880.39%
Apr 17, 2023
Assumes: Overweight
Price Target: $44
Current: $8.43
Upside: +421.95%
Feb 8, 2023
Maintains: Overweight
Price Target: $100
Current: $64.93
Upside: +54.01%